Prolight obtains patent potentially representing a new business opportunity
Prolight Diagnostics has obtained a European patent based on a cutting-edge solution for separating plasma from whole blood within a fluidic consumable. The separation generates high quality plasma, requires minimal physical space, and is completed in a short time, which opens new potential business opportunities by incorporating the technology into other disposable fluidic systems. The […]
Prolight Diagnostics publishes investor letter for september 2024
Prolight Diagnostics publishes its investor letter for September 2024. The letter includes updates on the rapid and cost-effective development of our proprietary, unique digital point-of-care analysis system, Psyros™, as well as several important external activities. link to the investor letter: https://prolightdx.com/investor-letters For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: […]
Prolight showcases Psyros™ to global key opinion leaders in cardiology at 2024 Cardiac Markers Dialogue Meeting
Prolight Diagnostics today announces its participation at the 2024 Cardiac Markers Dialogue Meeting, on 26th September and 27th September in Glasgow, UK. This prestigious event brings together key opinion leaders including leading researchers and healthcare professionals, to discuss advances in cardiac biomarker diagnostics and their implications for patient care. The 2024 meeting provides an invaluable […]
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
Read the full article here: https://www.emergers.se/prolight_e/ For further information, please contact:Ulf Bladin, CEOE-mail: ub@prolightdx.comPhone: +46 73 582 39 87 Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.We want to offer the foremost […]
Prolight Diagnostics presents the Psyros system at ADLM, one of the world’s largest and most important diagnostics congresses
Prolight Diagnostics (“Prolight”), developer of the Psyros™ digital point-of-care (POC) system for high-sensitivity troponin, announces that the platform will be showcased at DxPxduring the international congress ADLM in Chicago July 28-August 1, 2024. “We are very proud to present the latest commercial instrument prototype and the cartridge that will be used for high-sensitivity troponin assays. […]
Annual general meeting of Prolight Diagnostics AB (publ) on 27 May 2024
The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 27 May 2024 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight on track for clinical performance studies
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announces today that their latest data for troponin in whole blood confirm that the company is now ready to initiate trials with patient samples. The latest data were generated in whole blood samples on the final commercial cartridge design, which now includes internal cartridge quality controls […]
Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant
Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 […]
Prolight Diagnostics awarded SEK17M UK government grant in collaboration with leading UK hospital Trust
Prolight Diagnostics, developer of the digital point-of-care platform PsyrosTM, has been awarded an NIHR Invention for Innovation (i4i) Product Development Award (PDA) of SEK17M (£1.26M) in collaboration with among others, Guy’s and St Thomas’ NHS Foundation Trust, and King’s College London. “We are delighted to have been awarded this prestigious grant. The National Institute for […]
Prolight selects MDx CRO for the clinical performance studies for Psyros™
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed MDx CRO as its contract research partner for the clinical performance study to validate the Psyros™ high-sensitivity troponin test. After a rigorous selection process, Prolight is pleased to announce the appointment of MDxCRO as its clinical partner. The collaboration will focus on the clinical validation […]
